Unum therapeutics inc. (UMRX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities:
Net loss

-6,094

2,297

-11,923

-10,516

-11,691

-8,606

-10,168

-9,023

-6,735

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-5,863

-5,939

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense

295

314

318

331

330

352

330

325

314

307

300

286

278

Stock-based compensation expense

769

842

788

885

726

902

860

847

479

460

299

282

300

Realized loss on sales of marketable securities

-

-

0

-1

-1

-

-

-

-

-

-

-

-

Noncash consideration received from a customer

808

-

-

-

-

-

-

-

-

-

-

-

-

Premiums paid on marketable securities

-

-

-

-

-

-

-

-

-

0

0

-1

14

Net amortization (accretion) of premiums (discounts) on marketable securities

-

-2

0

6

49

87

120

43

-4

-7

-5

-3

-2

Non-cash interest expense

-

-

-

-

-

7

5

6

5

6

5

5

4

Changes in operating assets and liabilities:
Accounts receivable

-2,000

1,120

-612

-548

372

249

217

-399

771

-681

253

371

-41

Prepaid expenses and other current assets

414

-468

-27

486

17

-213

-447

242

668

-331

262

121

185

Operating lease, right-of-use asset

-356

-349

-343

-339

-334

-

-

-

-

-

-

-

-

Other assets

-427

-1

1

0

427

0

0

0

419

-

-

-

-

Accounts payable

-2,555

1,589

-66

-176

317

716

-852

-838

1,341

-774

303

501

-61

Accrued expenses and other current liabilities

-1,008

593

609

-138

696

-124

2,780

1,135

-908

-

-

-

-

Accrued expenses and other current liabilities

-

-

-

-

-

-

-

-

-

-

-

338

-761

Deferred rent

-

-

-

-

-

-17

-17

-14

-4

-5

-4

-1

8

Operating lease liability

-387

-380

-374

-366

-352

-

-

-

-

-

-

-

-

Deferred revenue

-474

-13,402

-458

-1,760

-1,014

-2,137

-623

-465

-619

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-820

-821

-941

Net cash used in operating activities

-7,893

-8,445

-10,207

-11,344

-11,518

-9,020

-7,575

-7,913

-7,981

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-7,268

Cash flows from investing activities:
Purchases of property and equipment

-

13

-22

0

42

0

86

388

75

100

275

217

320

Purchases of marketable securities

-

-

-

-

-

-

-

-

-

0

0

2,000

4,500

Proceeds from maturities and sales of marketable securities

-

0

0

7,996

14,992

15,000

10,000

6,700

6,000

5,000

6,000

6,000

4,000

Net cash provided by investing activities

-

-13

226

7,996

14,950

15,000

9,914

-41,370

5,925

-

-

-

-

Cash flows from financing activities:
Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-820

Proceeds from issuance of common stock upon stock option exercises

38

0

0

97

11

395

175

11

28

-

-

-

-

Proceeds from issuance of stock from employee stock purchase plan

35

-

-

-

-

-

-

-

-

-

-

-

-

Payments of initial public offering costs

-

-

-

-

-

0

0

1,493

563

-

-

-

-

Net cash provided by financing activities

73

0

0

97

11

395

175

70,311

-535

-

-

-

-

Net (decrease) increase in cash, cash equivalents and restricted cash

-7,820

-8,458

-9,981

-3,251

3,443

6,375

2,514

21,028

-2,591

-

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-1,978

-8,088

Supplemental disclosure of noncash investing and financing information:
Purchases of property and equipment included in accounts payable

-

-

-

-

-

-

-

-27

108

-

-

-

-

Deferred offering costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

956

-

-

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

0

0

0

16

16

16

17

16